Next Article in Journal
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial
Previous Article in Journal
The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review
Open AccessArticle

Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)

1
Medical Oncology Department, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Spain
2
Medical Oncology Department, Hospital General Universitario de Elche, 03203 Elche, Spain
3
Medical Oncology Department, Hospital General Universitario de Alicante, 03010 Alicante, Spain
4
Medical Oncology Department, Hospital Universitari Sant Joan de Reus. URV. IISPV, 43204 Reus, Spain
5
Medical Oncology Department, Instituto Valenciano de Oncología, 46009 Valencia, Spain
6
Medical Oncology Department, Hospital Universitario la Fe, 46026 Valencia, Spain
7
Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(2), 1249-1255; https://doi.org/10.3390/curroncol28020118
Received: 21 February 2021 / Revised: 8 March 2021 / Accepted: 12 March 2021 / Published: 16 March 2021
(This article belongs to the Section Hematology)
The new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) coronavirus has generated a pandemic, in which there are population groups at higher risk and who are potentially fatal victims of the disease. Cancer patients have been considered a group with special susceptibility, particularly patients with lung tumour involvement and haematological neoplasms. The Spanish Lymphoma Oncology Group (GOTEL) carried out a multicenter study of SARS-CoV-2 seroprevalence in patients with lymphoma. Results: A total of 150 patients were included between 22 May and 11 June 2020. The mean age was 65 years (range 17–89), 70 women (46.5%) and 80 men (53, 5%). At the time of diagnosis of lymphoma, 13 cases were stage I (9%), 27 (18%) stage II, 37 (24.5%) stage III, and 73 (48.5%) stage IV, while 6.6% had a primary extranodal origin. A total of 10 cases with positive serology for SARS-CoV-2 were identified, which is a prevalence of 6% in this population. None of the patients required intensive care unit management and all fully recovered from the infection. Conclusion: IgG antibody seroprevalence in lymphoma patients appears similar to that of the general population and does not show greater aggressiveness. View Full-Text
Keywords: lymphoma; infection of SARS-CoV-2; Covid-19 lymphoma; infection of SARS-CoV-2; Covid-19
MDPI and ACS Style

Franco, F.; Guirado, M.; Martínez-Banaclocha, N.; Gumà, J.; Lavernia, J.; Gómez-Codina, J.; Rodriguez-Abreu, D.; Martínez, F.; Barrajón, E.; Méndez, M.; Calvo, V.; Provencio, M. Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel). Curr. Oncol. 2021, 28, 1249-1255. https://doi.org/10.3390/curroncol28020118

AMA Style

Franco F, Guirado M, Martínez-Banaclocha N, Gumà J, Lavernia J, Gómez-Codina J, Rodriguez-Abreu D, Martínez F, Barrajón E, Méndez M, Calvo V, Provencio M. Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel). Current Oncology. 2021; 28(2):1249-1255. https://doi.org/10.3390/curroncol28020118

Chicago/Turabian Style

Franco, Fernando; Guirado, María; Martínez-Banaclocha, Natividad; Gumà, Josep; Lavernia, Javier; Gómez-Codina, José; Rodriguez-Abreu, Delvys; Martínez, Fani; Barrajón, Enrique; Méndez, Miriam; Calvo, Virginia; Provencio, Mariano. 2021. "Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)" Curr. Oncol. 28, no. 2: 1249-1255. https://doi.org/10.3390/curroncol28020118

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop